ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Nextech to Discuss Responsible AI in Healthcare at Eyecelerator

TAMPA, Fla., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Nextech, market leader of comprehensive technology solutions for specialty physician practices, today announced Chief Medical Officer Dr. Jason Handza will present on the responsible use of artificial intelligence (AI) in improving clinical and patient outcomes at Eyecelerator, a conference about trends and innovations in eyecare. Attendees can watch Handza’s presentation at 2:07 p.m. Oct. 17 in room 451B of McCormick Place in Chicago.

“We believe that through the responsible use of AI we can significantly improve clinical operations,” Handza said. “These improvements also have the potential to drive significantly better patient and healthcare outcomes.”

Handza is a practicing physician with 20 years of experience in ophthalmology. His expertise helps strategically guide excellence in product design and development for the Nextech technology platform to drive better practice and patient outcomes.

Eyecelerator, a partnership between the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery, features key opinion leaders and highlights industry advancements, investment trends, and innovative new products disrupting eyecare. The event is committed to accelerating ophthalmic innovation by connecting the scientific talent and entrepreneurs advancing eyecare with mission-driven investors and business partners who support their success.

Nextech also will be exhibiting at the AAO 2024 conference from Oct. 18-21. Stop by Booth 2308 to learn more about Nextech or visit www.nextech.com.

About Nextech

Nextech is the complete healthcare technology solution for specialty providers. Since 1997, Nextech has been focused on delivering innovative solutions and services that drive efficiency, fuel growth, and enhance the patient care experience. Nextech services more than 16,000 physicians and over 60,000 office staff members in the clinical specialties of dermatology, med spa, ophthalmology, orthopedics, and plastic surgery. 

About Eyecelerator

Eyecelerator, originally called Ophthovation, is a partnership between the American Society of Cataract and Refractive Surgery (ASCRS) and the American Academy of Ophthalmology to connect entrepreneurs, investors, businesses and ophthalmologists to accelerate ophthalmic innovation and improve patient outcomes. For more information, visit https://eyecelerator.com.

About the American Society of Cataract and Refractive Surgery

ASCRS is an international educational society with nearly 8,000 ophthalmic surgeons at every career stage. Its mission is to empower anterior segment surgeons to improve the vision, outcomes and quality of life for their patients through innovative approaches to education, advocacy and philanthropy. For more information, visit ascrs.org.

About the American Academy of Ophthalmology

The academy is the world’s largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, it protects sight and empowers lives by setting the standards for ophthalmic education and advocating for its patients and the public. The academy innovates to advance the profession and to ensure the delivery of the highest-quality eye care. Through its EyeSmart® articles on AAO.org, the academy provides the public with the most trusted information about eye health. For more information, visit aao.org. 

Ian Hoffman

Chief Marketing Officer

i.hoffman@nextech.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.22
+21.36 (9.58%)
AAPL  270.37
-1.03 (-0.38%)
AMD  256.12
+1.28 (0.50%)
BAC  53.45
+0.42 (0.79%)
GOOG  281.82
-0.08 (-0.03%)
META  648.35
-18.12 (-2.72%)
MSFT  517.81
-7.95 (-1.51%)
NVDA  202.49
-0.40 (-0.20%)
ORCL  262.61
+5.72 (2.23%)
TSLA  456.56
+16.46 (3.74%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.